iBio Reports Preclinical Data Showing IBIO-610 Helps Preserve Muscle During GLP-1 Weight Loss
Biotechnology firm iBio, Inc. (NASDAQ:IBIO) highlighted preclinical data demonstrating that its drug candidate, IBIO-610, reduced lean muscle loss when combined with the weight-loss medication semaglutide. In an eight-week study involving obese non-human primates, animals treated with a combination of IBIO-610 and semaglutide saw fat account for 93% of total weight lost, compared to 77% for those receiving semaglutide alone. Lean mass accounted for only 6% of weight lost under the combination treatment, compared to 22% with semaglutide by itself.
GLP-1 receptor agonists like semaglutide are effective for weight reduction, but patients often experience significant muscle loss alongside fat reduction. IBIO-610 is an Activin E antibody candidate designed to address this issue. In the primate study, a single dose of IBIO-610 reduced active Activin E levels in blood serum by 97% at week eight, demonstrating a 33.2-day half-life in primates that may support twice-yearly dosing in humans.
iBio expects to advance IBIO-610 into first-in-human clinical trials during the first half of 2027. Investors and industry observers will monitor whether these preclinical body-composition results translate into similar outcomes in future human studies.
Key points
- In an eight-week study on primates, IBIO-610 combined with semaglutide limited lean mass loss to 6% of total weight lost, compared to 22% for semaglutide alone.
- Animals receiving the combination therapy had 93% of their weight loss come from fat, compared with 77% for semaglutide alone.
- A single dose of IBIO-610 achieved a 97% reduction in active Activin E levels at week eight, with a 33.2-day half-life in primates.
- iBio plans to initiate first-in-human clinical trials for IBIO-610 in the first half of 2027.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is IBIO-610 and how does it work?
IBIO-610 is an Activin E antibody candidate developed by iBio, Inc. to help preserve lean muscle mass when used alongside GLP-1 weight-loss therapies like semaglutide.
What were the results of the IBIO-610 primate study?
When combined with semaglutide, IBIO-610 reduced lean muscle loss to 6% of total weight lost, compared to 22% for semaglutide alone, with 93% of total loss coming from fat.
When will clinical trials for IBIO-610 begin?
iBio expects to start first-in-human clinical trials for IBIO-610 in the first half of 2027.